This article was originally published on this site
Regulus Therapeutics Inc. (RGLS) had a rough trading day for Friday July 13 as shares tumbled 7.56%, or a loss of $-0.0245 per share, to close at $0.30. After opening the day at $0.33, shares of Regulus Therapeutics Inc. traded as high as $0.33 and as low as $0.29. Volume was 1.77 million shares over 2,604 trades, against an average daily volume of 551,404 shares and a total float of 104.32 million.
As a result of the decline, Regulus Therapeutics Inc. now has a market cap of $31.24 million. In the last year, shares of Regulus Therapeutics Inc. have traded between a range of $1.52 and $0.30, and its 50-day SMA is currently $0.67 and 200-day SMA is $0.94.
For a complete fundamental analysis of Regulus Therapeutics Inc., check out Equities.com’s Stock Valuation Analysis report for RGLS.
Still paying commissions on stock trades? Equities.com now offers 100% commission free stock trading and flat-fee options trading for $89.95/month! Get started today by https://www.equities.com/trading
Regulus Therapeutics Inc is a biotechnology company that focuses on the development of microRNA therapies. MicroRNA is a noncoding ribonucleic acid that regulates most genes in the genome.
Regulus Therapeutics Inc. is based out of San Diego, CA and has some 63 employees. Its CEO is Joseph P. Hagan.
Regulus Therapeutics Inc. is a component of the Russell 2000. The Russell 2000 is one of the leading indices tracking small-cap companies in the United States. It’s maintained by Russell Investments, an industry leader in creating and maintaining indices, and consists of the smallest 2000 stocks from the broader Russell 3000 index.
Russell’s indices differ from traditional indices like the Dow Jones Industrial Average (DJIA) or S&P 500, whose members are selected by committee, because they base membership entirely on an objective, rules based methodology. The 3,000 largest companies by market cap make up the Russell 3000, with the 2,000 smaller companies making up the Russell 2000. It’s a simple approach that gives a broad, unbiased look at the small-cap market as a whole.
To get more information on Regulus Therapeutics Inc. and to follow the company’s latest updates, you can visit the company’s profile page here: RGLS’s Profile. For more news on the financial markets and emerging growth companies, be sure to visit Equities.com’s Newsdesk. Also, don’t forget to sign-up for our daily email newsletter to ensure you don’t miss out on any of our best stories.
All data provided by QuoteMedia and was accurate as of 4:30PM ET.
DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer